𝔖 Bobbio Scriptorium
✦   LIBER   ✦

866 PROSTATE-SPECIFIC ANTIGEN AND SERUM ALKALINE PHOSPHATASE LEVELS IN PROSTATE CANCER PATIENTS RECEIVING DEGARELIX OR LEUPROLIDE

✍ Scribed by Crawford, E. David; Moul, Judd W.; Shore, Neal D.; Kold Olesen, Tine; Persson, Bo-Eric

Book ID
121969658
Publisher
Lippincott Williams and Wilkins
Year
2010
Tongue
English
Weight
144 KB
Volume
183
Category
Article
ISSN
0022-5347

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Changes in alkaline phosphatase levels i
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study
✍ Fritz H. Schröder; Bertrand Tombal; Kurt Miller; Laurent Boccon-Gibod; Neal D. S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB

Study Type – Therapy (RCT)
Level of Evidence 1b ## OBJECTIVE To compare the activity of degarelix, a new gonadotrophin‐releasing hormone (GnRH) blocker, with leuprolide depot 7.5 mg in the control of total serum alkaline phosphatase (S‐ALP) levels in patients with prostate cancer. ## PATIENTS AND

Higher prostate-specific antigen levels
Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase
✍ Wanling Xie; Mari Nakabayashi; Meredith M. Regan; William K. Oh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

## Abstract ## BACKGROUND. Higher prostate‐specific antigen (PSA) and alkaline phosphatase (ALK‐P) levels predicted worse survival in men with metastatic hormone‐refractory prostate cancer (HRPC). In the current study, the authors evaluated the combined effects of PSA and ALK‐P on survival. ## ME